Literature DB >> 16329570

Human papillomavirus related diseases in Malaysians.

P L Cheah1.   

Abstract

The surge of information on the aetiological association of the human papillomavirus (HPV) with some epithelial tumours emanating from various centres has prompted the initiation of a large-scale retrospective study at the Department of Pathology, University Hospital Kuala Lumpur to determine the prevalence and importance of this virus in some epithelial tumours of Malaysian patients. A retrospective analysis of 100 cases of large cell non-keratinising carcinoma of the uterine cervix by in-situ hybridisation on archival formalin-fixed, paraffin-embedded tissue has revealed the presence of HPV type 16 in 47% and type 18 in 41% of cases. This gives an overall detection rate of 88% of the two HPV types most commonly encountered in cervical carcinomas. Except for the unusually high frequency of HPV 18 detected in the cases, the overall prevalence is comparable to that reported in studies from most other centres. Although this higher frequency of HPV 18 may be due to geographical variation, the selection of the large cell non-keratinising type of squamous cell cervical carcinoma for study remains a possible reason for this phenomenon. In comparison to cervical carcinomas, HPV appears to be uncommon in penile carcinomas and HPV 6 was detected in only 1 of 23 cases studied.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 16329570

Source DB:  PubMed          Journal:  Malays J Pathol        ISSN: 0126-8635            Impact factor:   0.656


  2 in total

Review 1.  Current issues facing the introduction of human papillomavirus vaccine in malaysia.

Authors:  Lp Wong; Ic Sam
Journal:  Malays Fam Physician       Date:  2007-08-31

2.  Awareness of cervical cancer among women in Malaysia.

Authors:  Lee Mun Seng; Aina Najwa Rosman; Almas Khan; Najwa Md Haris; Nur Alyan Syahmi Mustapha; Nur Sakina Muhammad Husaini; Nurul Fadhilah Zahari
Journal:  Int J Health Sci (Qassim)       Date:  2018 Jul-Aug
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.